Long-term survival in transfusion recipients in Sweden, 1993

Transfusion

Volumn 41, Issue 2, 2001, Pages 251-255

  Tynell, Elsa ^a,b,c   Norda, Rut ^a,b,c   Shanwell, Agneta ^a,b,c   Björkman, Anders ^a,b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

^c ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; SCREENING TEST; SURVIVAL; SWEDEN;

AGED; BLOOD TRANSFUSION; HEPATITIS C; HIV INFECTIONS; HUMANS; SURVIVAL RATE; SWEDEN;

EID: 0035106877     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2001.41020251.x     Document Type: Article

References (16)

1. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988)
2. T-lymphotropic virus type I in Japan
3. HTLV-I/II infection among French blood donors
4. Prevalence of antibodies to human T-cell leukaemia/lymphoma virus in blood donors in north London
5. Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: Cost effectiveness analysis
6. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type I infections
7. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood
8. Cost-effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries
9. Declining yield of alanine aminotransferase for screening of blood donors for prevention of post-transfusion hepatitis B and C virus infection
10. A practical guideline and decision aid for blood transfusion
11. Risk of AIDS for recipients of blood components from donors who subsequently developed AIDS
12. The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease
13. Long-term mortality after transfusion-associated non-A, non-B hepatitis
14. Long-term survival after blood transfusion
15. The transfused population of Canterbury, New Zealand, and its mortality
16. Buffy-coat derived platelet concentrates prepared from half-strength citrate CPD and CPD whole-blood units. Comparison between three additive solutions: In vitro studies